Basking Ridge, NJNCT06377566Now EnrollingIRB Ready

Hodgkin Lymphoma Clinical Trial in Basking Ridge, NJ

Access cutting-edge hodgkin lymphoma treatment through this phase 2 clinical trial at a research site in Basking Ridge. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Basking Ridge location

Preparing your pre-screening questions…

Expert Care in Basking Ridge

Access hodgkin lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hodgkin lymphoma treatment provided free

Apply for This Basking Ridge Location

Check if you qualify for this hodgkin lymphoma clinical trial in Basking Ridge, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Basking Ridge

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Basking Ridge site if eligible
  4. 4Begin participation

About This Hodgkin Lymphoma Study in Basking Ridge

The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called an antibody-drug conjugate (ADC). ADCs are a substance made up of a monoclonal antibody chemically linked to a drug. Antibodies are proteins made by the immune system to fight infections and other possible harms to the body. The monoclonal antibody b

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Histological diagnosis of classical, CD30-positive Hodgkin lymphoma confirmed at enrolling institution.
Ann Arbor stage I or II FDG-avid disease by FDG-PET/CT.
Disease bulk defined as any lymph node mass with transverse maximal diameter ≥ 7.0 cm or coronal maximal diameter ≥ 7.0 cm on CT imaging.
Age 18 and over.
ECOG Performance Status ≤ 2
Females of childbearing age must be on an acceptable form of birth control per institutional standards during the treatment period.
Males must consistently use an acceptable form of contraception per institutional standards during the treatment period.

Exclusion Criteria

Prior systemic therapy or radiation therapy for Hodgkin lymphoma (excluding corticosteroids)
Cardiac ejection fraction \< 50% as measured by echocardiogram.
Platelet count ≤ 75,000/µL.
Hemoglobin level ≤ 7.0 mg/dL.
Absolute neutrophil count ≤ 1.0 K/µL.
Serum creatinine clearance \< 30 mL/minute as estimated by the Cockcroft-Gault Method.
Transaminase levels \> 3 times the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, \> 5 times the upper limit of normal is exclusionary.
Total bilirubin ≥ 1.5 the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, \> 3 times the upper limit of normal is exclusionary.
Pre-existing peripheral neuropathy ≥ grade 2 prior to participation.
Known pregnancy or breast-feeding
Active viral infection with hepatitis B or hepatitis C. For hepatitis B, patients who are seropositive (hepatitis B core Ab positive) are permitted if HBV DNA is negative by PCR. For hepatitis C, patients who are seropositive (hepatits C Ab positive) are eligible if HCV DNA is negative by PCR and curative therapy has been completed.
Concurrent malignancy requiring active therapy within the last 2 years with the exception of basal cell or squamous cell carcinoma limited to the skin, carcinoma in situ of the cervix, breast or localized prostate cancer. Adjuvant hormonal therapy for cancer previously treated for curative intent is permitted.
Patients with autoimmune conditions requiring active, ongoing systemic immunosuppressive therapy.
Medical illness unrelated to Hodgkin lymphoma which in the opinion of the treating physician and/or principal investigator makes participation inappropriate. Note: Patients with HIV infection are permitted to enroll but are required to be on antiretroviral regimens that are in accordance with the current International AIDS Society guidelines concurrently with chemotherapy. Use of experimental antiretroviral agents or those containing zidovudine or ritonavir, cobicistat or similar potent CYP3 inhibitors are prohibited. In order to be eligible, patients taking zidovudine or ritonavir, or cobicistat or other CYP3 inhibitors must change to a different regimen 7 days prior to therapy initiation. Subjects must be on HAART for at least 12 weeks prior to therapy. Note: Patients with pre-existing autoimmune conditions are NOT excluded unless there is an autoimmune condition requiring active, ongoing systemic immunosuppressive therapy. However, careful consideration should be given to patients with pre-existing autoimmune conditions who may need pembrolizumab. Any concerns regarding patients with pre-existing autoimmune conditions and eligibility should be reviewed with the study PI.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Basking Ridge?

Yes, this clinical trial (NCT06377566) has an active research site in Basking Ridge, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hodgkin Lymphoma Treatment Options in Basking Ridge, NJ

If you're searching for hodgkin lymphoma treatment options in Basking Ridge, NJ, this clinical trial (NCT06377566) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Basking Ridge research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hodgkin lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Basking Ridge, NJ

See all lymphoma clinical trials recruiting in Basking Ridge — not just this study.

Browse Lymphoma Trials in Basking Ridge →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Basking Ridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Basking Ridge, NJ